BR112022009066A2 - Ezetimiba para uso em tratamento de câncer - Google Patents
Ezetimiba para uso em tratamento de câncerInfo
- Publication number
- BR112022009066A2 BR112022009066A2 BR112022009066A BR112022009066A BR112022009066A2 BR 112022009066 A2 BR112022009066 A2 BR 112022009066A2 BR 112022009066 A BR112022009066 A BR 112022009066A BR 112022009066 A BR112022009066 A BR 112022009066A BR 112022009066 A2 BR112022009066 A2 BR 112022009066A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- ezetimiba
- treatment
- ezetimibe
- derivative
- Prior art date
Links
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 4
- 229960000815 ezetimibe Drugs 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 abstract 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract 2
- 229940109262 curcumin Drugs 0.000 abstract 2
- 235000012754 curcumin Nutrition 0.000 abstract 2
- 239000004148 curcumin Substances 0.000 abstract 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
EZETIMIBA PARA USO EM TRATAMENTO DE CÂNCER. A invenção é direcionada ao uso de ezetimiba ou a um sal ou derivado medicamento aceitável na fabricação de uma composição farmacêutica para o tratamento de um câncer de superexpressão de Mdm2. Também é direcionado ao uso de ezetimiba, ou um sal ou derivado farmaceuticamente aceitável, em combinação com curcumina na fabricação de uma composição farmacêutica para o tratamento de um câncer de cólon Mdm2-superexpresso. A invenção é ainda dirigida a uma composição farmacêutica composta por ezetimiba, ou um sal ou derivado farmaceuticamente aceitável, e curcumina para uso em um método de tratamento de câncer de superexpressão de Mdm2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA201907474 | 2019-11-12 | ||
| PCT/IB2020/060599 WO2021094933A1 (en) | 2019-11-12 | 2020-11-11 | Ezetimibe and curcumin for use in cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009066A2 true BR112022009066A2 (pt) | 2022-08-09 |
Family
ID=73498091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009066A BR112022009066A2 (pt) | 2019-11-12 | 2020-11-11 | Ezetimiba para uso em tratamento de câncer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220387383A1 (pt) |
| EP (1) | EP4058004B1 (pt) |
| CN (1) | CN114786657A (pt) |
| BR (1) | BR112022009066A2 (pt) |
| WO (1) | WO2021094933A1 (pt) |
| ZA (1) | ZA202206308B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116368124A (zh) * | 2020-08-04 | 2023-06-30 | 南非大学 | 用于癌症治疗的修饰的依泽替米贝药物 |
| CN115364094A (zh) * | 2021-05-19 | 2022-11-22 | 南京大学 | 伊折麦布在制备抗肿瘤药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006501205A (ja) * | 2002-07-30 | 2006-01-12 | カリキオン インコーポレイテッド | エゼチミブ組成物、並びにコレステロールに関連した良性および悪性の腫瘍を治療する方法 |
| CN101468944A (zh) * | 2007-12-24 | 2009-07-01 | 北京琥珀光华医药科技开发有限公司 | 一种姜黄有效成分姜黄素的提取分离方法 |
| CN104784117B (zh) * | 2015-04-22 | 2017-08-08 | 山东大学 | 一种姜黄素混合胶束口服制剂及其制备方法 |
| CN105412046B (zh) * | 2015-12-31 | 2019-03-08 | 河北医科大学 | 一种姜黄素结肠靶向药物制剂及其制备方法 |
-
2020
- 2020-11-11 US US17/776,276 patent/US20220387383A1/en active Pending
- 2020-11-11 WO PCT/IB2020/060599 patent/WO2021094933A1/en active Search and Examination
- 2020-11-11 BR BR112022009066A patent/BR112022009066A2/pt unknown
- 2020-11-11 EP EP20811102.1A patent/EP4058004B1/en active Active
- 2020-11-11 CN CN202080086186.0A patent/CN114786657A/zh active Pending
-
2022
- 2022-06-07 ZA ZA2022/06308A patent/ZA202206308B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202206308B (en) | 2023-10-25 |
| EP4058004A1 (en) | 2022-09-21 |
| US20220387383A1 (en) | 2022-12-08 |
| CN114786657A (zh) | 2022-07-22 |
| WO2021094933A1 (en) | 2021-05-20 |
| EP4058004B1 (en) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112019024674A2 (pt) | Inibidores covalentes da kras | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| EP3777888A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| BR112017023233A2 (pt) | métodos para tratamento de câncer | |
| BR112015011497A2 (pt) | composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| BR112012012918A2 (pt) | agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes. | |
| CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
| BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
| BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
| BR112022009066A2 (pt) | Ezetimiba para uso em tratamento de câncer | |
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| BR112015006738A2 (pt) | terapia de combinação usando belinostat e trabectedina | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| BR112022012280A2 (pt) | Combinações | |
| BR112022012281A2 (pt) | Combinações | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| BR112019006174A2 (pt) | proteina terapêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |